What pre‑injection history should be obtained before administering an Antara (medroxyprogesterone acetate) injection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Pre-Injection History for Antara (Medroxyprogesterone Acetate) Injection

The most critical pre-injection history element is establishing reasonable certainty that the woman is not pregnant, which can be accomplished through a structured assessment of menstrual timing, recent sexual activity, and current contraceptive use. 1

Essential History Components

1. Pregnancy Exclusion (Class A - Mandatory)

The primary historical assessment must establish that the woman is not pregnant. According to CDC guidelines, DMPA can be given at any time if it is "reasonably certain" the woman is not pregnant 1. This determination requires:

  • Last menstrual period (LMP): Date and character of last bleeding
  • Recent sexual activity: Timing and frequency since LMP
  • Current contraceptive use: Method and consistency of use
  • Pregnancy symptoms: Absence of nausea, breast tenderness, missed periods

If uncertainty exists about pregnancy status, the benefits of starting DMPA likely exceed any risk; therefore, starting DMPA should be considered at any time, with a follow-up pregnancy test in 2-4 weeks 1.

2. Timing-Specific History

The history must establish the woman's current reproductive status to determine timing and need for backup contraception:

Regular Menstrual Cycles:

  • If within first 7 days of menstrual bleeding: No backup contraception needed 1
  • If >7 days since menstrual bleeding started: Requires 7 days of backup contraception 1

Postpartum (Breastfeeding):

  • Time since delivery
  • Breastfeeding status (exclusive vs. partial)
  • Return of menses
  • If <6 months postpartum, amenorrheic, and fully/nearly fully breastfeeding (≥85% of feeds): No backup needed 1

Postpartum (Not Breastfeeding):

  • Days since delivery (≥21 days)
  • Return of menstrual cycles 1

Post-abortion:

  • Type (spontaneous vs. induced, surgical vs. medical)
  • Timing (within 7 days allows immediate administration) 1

Switching from Another Method:

  • Current method and last use
  • Special consideration for IUD users: timing of sexual activity relative to menstrual cycle 1

3. Medical Contraindications Assessment

While the guidelines emphasize that no routine examinations or tests are needed before DMPA initiation among healthy women 1, specific historical screening is essential:

Absolute Contraindications (Must Screen):

  • Current pregnancy (primary concern)
  • Unexplained vaginal bleeding (until evaluated)
  • Known or suspected breast cancer
  • Severe liver disease (active hepatitis, cirrhosis)
  • Severe renal impairment (eGFR <30 mL/min/1.73m²) 1

Conditions Requiring Caution:

  • History of thromboembolic disease
  • Cardiovascular disease
  • Diabetes with vascular complications
  • Migraine with aura
  • Current or history of depression
  • Bone health concerns (adolescents, prolonged immobilization)

4. Medication History

  • Current medications: Particularly enzyme-inducing drugs, anticoagulants
  • Allergies: To medroxyprogesterone acetate or any formulation components

5. Counseling-Related History

  • Contraceptive goals: Duration of desired contraception
  • Previous contraceptive experience: Methods tried, reasons for discontinuation
  • Menstrual preferences: Tolerance for irregular bleeding or amenorrhea
  • Understanding of method: Previous knowledge about DMPA

What Does NOT Need to Be Obtained

According to evidence-based guidelines, the following are NOT required before DMPA initiation in healthy women 1:

  • Blood pressure measurement (Class C)
  • Pelvic examination (Class C)
  • Cervical cancer screening (Class C)
  • STI screening (unless clinically indicated)
  • Lipid profile
  • Glucose testing (unless diabetes suspected)
  • Liver enzymes
  • Hemoglobin/hematocrit
  • Baseline weight/BMI (though may be useful for monitoring over time)

Critical Counseling Points to Document

Before administration, document discussion of:

  • Expected bleeding changes: Irregular bleeding initially, amenorrhea common with continued use (occurs in majority by 1 year) 1
  • Reversibility: Delayed return to fertility (average 10 months from last injection)
  • Injection schedule: Every 12 weeks (13 weeks), with 2-week grace period 1
  • Common side effects: Weight gain, headaches, mood changes
  • Bone density concerns: Particularly for adolescents and women with risk factors
  • STI protection: DMPA does not protect against STIs; condom use recommended 1

Common Pitfalls to Avoid

  1. Delaying initiation unnecessarily: Waiting for next menstrual period is unnecessary if pregnancy can be reasonably excluded 1
  2. Over-testing: Requiring unnecessary laboratory tests or examinations that delay access 1
  3. Inadequate bleeding counseling: Failure to prepare women for menstrual changes is the primary reason for discontinuation
  4. Missing contraindications: Particularly severe renal impairment and active liver disease
  5. Inadequate pregnancy assessment: Not using structured criteria to establish reasonable certainty of non-pregnancy

The history should be focused, efficient, and aimed at excluding pregnancy and absolute contraindications while providing adequate counseling about expected effects—particularly menstrual changes—which are the most common reason for discontinuation despite being medically benign.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.